Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07079969

Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis (EPIC-KO)

This study aims to determine analgesic and anti-inflammatory effects of dual-wavelength PBM in people with symptomatic knee OA.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

50 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Florida

Gainesville, Florida, 32610, United States

Location contact

Margarete C Ribeiro-Dasilva

PRINCIPAL_INVESTIGATOR

Roger B Fillingim, PhD

SUB_INVESTIGATOR

Roland Staud, MD, FACP

SUB_INVESTIGATOR

Selenia Rubio, MD., MBA

CONTACT

[email protected]

352-273-5590

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically confirmed knee osteoarthritis (OA) based on the American College of Rheumatology (ACR) criteria with symptomatic pain for ≥ 3 months
  • Average knee-pain intensity ≥ 30/100 on both the Daily Symptom Diary (DSD) run-in and CATI
  • Age ≥ 50 years
  • Ability to give informed consent, attend visits, and complete ≥ 4 of 7 DSD entries pre-randomization
  • Capacity to perform all study tasks (Timed Up-and-Go, knee OA assessments, blood draw, questionnaires, etc)

Exclusion criteria

Systemic and Rheumatic Disease

  • Active systemic rheumatic condition (e.g., rheumatoid arthritis, systemic lupus erythematosus)
  • Fibromyalgia with pain outside the knee that is equal to or worse than knee pain

Musculoskeletal History

  • Clinically significant surgery on the index knee (e.g., arthroplasty, osteotomy)
  • Knee surgery within the past 6 weeks
  • Intra-articular injection to the index knee within the past 14 days

Medication Use

  • Daily opioid therapy
  • Hypersensitivity to PBM
  • Migraine triggered by light
  • Open wounds, skin infections, eczema, burns, or other dermatologic conditions at or near the treatment application site.
  • New prescription or OTC analgesic, non-pharmacologic pain therapy, chemotherapy, or radiation therapy initiated ≤ 30 days before screening

Cardiovascular Safety

  • Uncontrolled hypertension (SBP > 150 mmHg or DBP > 95 mmHg)
  • Unstable or activity-limiting cardiovascular or peripheral arterial disease

Neurological and Psychiatric Conditions

  • Diagnosed neurological disorder (e.g., Parkinson's disease, multiple sclerosis, epilepsy)
  • History or evidence of stroke or moderate-severe traumatic brain injury
  • Serious psychiatric illness requiring hospitalization within the past 12 months
  • Active suicidal ideation
  • Current substance-use disorder or past hospitalization for substance-use treatment

Dermatologic Conditions

  • Compromised skin integrity at or near the treatment site (e.g., open wounds, active rash, dermatitis, burns, ulcers, eczema, infection) interfering with topical treatment or PBM

Other Metabolic Conditions

  • Uncontrolled diabetes
  • Diabetes-related complications (e.g., peripheral neuropathy, severe nephropathy, chronic ulcers at treatment site)

Other Pain Conditions

  • Chronic pain at another body site more severe than knee pain

General Health and Cognition

  • Pregnancy or lactation
  • Cognitive impairment that precludes informed consent or task participation

Treatment and study plan

Photobiomodulation therapy (PBM) device

Device

FDA-cleared near-infrared PBM device delivering therapeutic light to the affected knee. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks (2-3 times per week).

Other names: light therapy

Sham PBM device

Device

Identical in appearance to the active PBM device but emits no therapeutic light. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks.

Other names: placebo light therapy

Primary outcomes

  1. Change in Knee Pain Intensity (Numeric Rating Scale)

    Time frame: Baseline (Visit 0) to Final Follow-up (Visit 7; approximately 3-4 weeks after baseline)

    Knee pain will be assessed using the 0-10 Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Assessments will be conducted at baseline (V0) and at the final follow-up visit, one week after the last treatment session.

Study contacts

Contact information is provided by the study sponsor or research team.

Selenia Rubio, MD. MBA,

CONTACT

[email protected]

352-273-5590

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Registry information

Official study title

Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis

Acronym: EPIC-KO

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 23, 2025
Registry last updated
May 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.